OC
CMPS

Oppenheimer & Co’s Compass Pathways CMPS Stock Holding History

Oppenheimer & Co’s Portfolio CMPS Stock Details CMPS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,366
Closed -$85.8K – 1389
2023
Q2 		$85.8K Buy
+10,366
New +$88K ﹤0.01% 1361

Other funds holding CMPS

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AM
AGF Management Toronto, Ontario, Canada $22.3B AUM 46.42% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Oppenheimer & Co's CMPS Position: Q3 2023 in Review

Oppenheimer & Co sold out of Compass Pathways (CMPS) in Q3 2023, closing a stake of 10,366 shares — an estimated $85.8K sold.

Oppenheimer & Co first reported a position in CMPS in Q2 2023 and held it in 1 quarter. The position peaked at $85.8K in Q2 2023. 113 funds tracked by Wall St. Rank hold CMPS as of Q3 2023.

  • Oppenheimer & Co reported no remaining Compass Pathways position as of Q3 2023 after selling out during the quarter.
  • Oppenheimer & Co sold 10,366 Compass Pathways shares in Q3 2023, an estimated $85.8K.
  • Oppenheimer & Co first reported a position in Compass Pathways in Q2 2023 and held it in 1 quarter.
  • Oppenheimer & Co's Compass Pathways position peaked at $85.8K in Q2 2023.
  • 113 funds tracked by Wall St. Rank held Compass Pathways as of Q3 2023.

Based on Oppenheimer & Co's 13F filing for Q3 2023, filed 8 Nov 2023.